Prediabetes and progression to type 2 diabetes — evidence across compounds
Every compound the Institute assesses in prediabetes and progression to type 2 diabetes, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in prediabetes and progression to type 2 diabetes, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| LiraglutideGLP-1 receptor agonist (acylated, once-daily) | Time to onset of type 2 diabetes over 160 weeks: hazard ratio 0.21 | HR 0.21 (95 % CI 0.13 to 0.34) | Moderate | 1 |
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | Progression to type 2 diabetes at 176 weeks reduced by 94 % in the prediabetes cohort | HR 0.06 (95 % CI 0.03 to 0.14) | Moderate | 1 |
| SemaglutideGLP-1 receptor agonist (acylated, long-acting) | Reversion to normoglycaemia in 84.1 % of participants with prediabetes at baseline versus 47.8 % with placebo (STEP 1) | not formally tested as a confirmatory endpoint | Low | 2 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
No evidence synthesis addresses this indication.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2016;375(4):311–322. doi:10.1056/NEJMoa1603827 · PMID 27295427
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.